![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.50 | 2.52% | 61.00 | 57.00 | 65.00 | 61.00 | 59.50 | 59.50 | 11,446 | 14:00:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investment Advice | 149k | -7.14M | -0.1082 | -5.64 | 39.26M |
RNS Number:8394Q Celsis International PLC 27 March 2008 CELSIS INTERNATIONAL PLC ("Celsis", "the Company" or "the Group") PRE CLOSE TRADING UPDATE STONG GROWTH QUARTER AT CELSIS 27 March 2008: Celsis International plc, the life sciences products and laboratory services company, today announces an update on trading prior to the commencement of its close period for the year ended 31 March 2008. The Company has made good progress during the year and has seen strong trading in the fourth quarter, following its Interim Management Statement update released on 7 February 2008. As a result, the Group overall is on track to announce revenue and profit growth in line with the Board's expectations for the financial year. The Rapid Detection division, which provides rapid microbial detection systems to more quickly ensure product safety and quality, has seen an excellent fourth quarter building on strong performance earlier in the year. This division's trend of increasing instrument placements and healthy reagent sales continues across all market segments as it focuses on expanding its presence in the rapidly growing microbial testing market. The Rapid Detection division has finalised the product design of its next generation nucleic acid technology that is complementary to its existing technology platform. Test market evaluations are scheduled to initiate following the end of the fiscal year with the launch of the product expected later this year. This new, advanced product line is designed to leap-frog existing nucleic acid testing platforms by significantly simplifying the assay procedure while providing real-time, specific organism intelligence that will provide customers a more acute response time to microbial contamination events. This incremental testing capability has been highlighted as a critical need by Celsis customers as product safety, quality and operational efficiencies increasingly become a major concern for customers. The In Vitro Technologies (Celsis IVT) division, which provides in vitro liver cell products and development services to the pharmaceutical and biotechnology industries to reduce the time and cost of drug discovery and development, has also benefited from a very positive fourth quarter adding to excellent earlier results. Celsis continues its strategy of aggressive growth for this business division and its first full year results are expected to be on track. Celsis IVT also announced today an exclusive global market development agreement with Apath LLC, a US based drug discovery company focused on human viral diseases, to assist customers in the evaluation of drug candidates for their cytotoxicity and efficacy against the Hepatitis C virus. The agreement is based on the intellectual property portfolio of Apath developed by its founder Charles M. Rice, Ph.D. and other pioneers in the field. The agreement not only provides sizeable incremental revenue potential to Celsis and is consistent with Celsis' position in providing leading technologies to our customers that provide critical information that assists in the drug discovery and development process. (See separate press release). The Analytical Services division, which provides outsourced laboratory testing services to the pharmaceutical industry, continues to see good progress from three of its four segments, but the slowdown of the Celsis New Jersey chemistry business has persisted into the fourth quarter. Although the Analytical Services business remains strong overall this division's growth is expected to be restrained by the New Jersey chemistry business. It is therefore expected to complete the full year down marginally against last year's excellent 25% increase in performance. Celsis will announce its preliminary results for the year ended 31 March 2008, on Wednesday 18 June 2008. There will be a presentation to analysts on the day at 9.30am, held at Financial Dynamics, Holborn Gate, 26 Southampton Buildings, London, WC2A 1PB. Jay LeCoque, Chief Executive Officer of Celsis, commented: "The increasing and combined strength of the Company is apparent and I am pleased to look forward to a positive year end performance with both revenue and profit growth in line with the Board's expectations. We have seen a continued strengthening of performance, particularly from the Rapid Detection and In Vitro Technologies divisions, and we believe that Celsis is well placed for future growth, both organically and through acquisition opportunities, which we continue to review. "As part of our commitment to remaining the global leader in our respective industries, I am particularly optimistic with our market development agreement with Apath, and I am extremely encouraged by the potential of this new business venture to help in the fight against Hepatitis C. I am also pleased with our Rapid Detection division's progress with its next generation nucleic acid technology and fully expect that this new product line to leap-frog existing tests on the market. These innovative developments underscore our growing strength in providing our customers with the best technology while offering the ease of use that Celsis is known for throughout the industry." Enquiries: Celsis International plc Tel: 01223 598 428 Jay LeCoque, Chief Executive Officer Christian Madrolle, Finance Director and Company Secretary Financial Dynamics Tel: 020 7831 3113 Ben Atwell David Yates Notes to editors Celsis International plc Celsis International plc is a world leading provider of innovative life science products and laboratory services to the pharmaceutical, biopharmaceutical, and consumer products industries through its three business areas; rapid detection, analytical and drug development services and ADME-Tox in vitro technologies. The company is listed on the London Stock Exchange (CEL.L) Each division of Celsis International plc has the capacity to deliver substantial time and cost savings to its customers, in addition to ensuring product quality and safety for consumers. Celsis Rapid Detection division utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market. Celsis Analytical Services division provides cost effective outsourced laboratory testing services to pharmaceutical and biopharmaceutical companies. Its comprehensive service offerings include a full spectrum of laboratory services from drug development and discovery to analytical chemistry and biological sciences to stability storage and testing. Celsis In Vitro Technologies (Celsis IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing products to the pharmaceutical and biotechnology industries. Celsis IVT's consumable testing products screen drug compounds for liver toxicity early in the drug discovery process, thereby reducing the time and cost of further development or trial on those compounds which will not be properly metabolised by the human liver. Further information can be found on its website at www.celsis.com. This information is provided by RNS The company news service from the London Stock Exchange END TSTILFSEVAIRFIT
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions